Pancreatic Cancer Research

ResearcherZhongda Hospital Southeast UniversityActive in the last 2 years

Jiahua Zhou

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0551-5604; OpenAlex author ID A5042829086. Sources: OpenAlex.

Their work

Papers
19 (first author 1, last author 14)
Trials
0
Grants
0
Labs led
1
Collaborators
25
Papers, trials and grants by year

2011: 2 papers · 2012: 1 paper · 2013: 1 paper · 2014: 1 paper · 2015: 1 paper · 2016: 1 paper · 2017: none · 2018: none · 2019: 1 paper · 2020: 3 papers · 2021: none · 2022: 3 papers · 2023: 1 paper · 2024: 3 papers · 2025: 1 paper

Papers 19

  1. ETV1 transcriptional manipulation of KIFC1 regulates the progression of pancreatic cancer. Last author DOI 10.32604/or.2025.059631↗
  2. Transcriptome data-based status of PI3K/AKT/mTOR pathway indicates heterogeneity and immune modulation in patients with pancreatic ductal adenocarcinoma. Last author DOI 10.1002/jgm.3570↗
  3. Transcriptomic landscape of endothelial cells: Key tumor microenvironment components indicating variable clinical outcomes in pancreatic ductal adenocarcinoma. Last author DOI 10.1002/tox.23881↗
  4. Identification of Transcriptomic Signatures of Pancreatic Ductal Adenocarcinoma-Derived Exosomes That Promote Macrophage M2 Polarization and Predict Prognosis:… Last author DOI 10.1177/11795549241239042↗
  5. mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance. Last author DOI 10.32604/or.2023.029309↗
  6. PMEPA1 interference activates PTEN/PI3K/AKT, thereby inhibiting the proliferation, invasion and migration of pancreatic cancer cells and enhancing the sensitiv… Last author DOI 10.1002/ddr.21844↗
  7. Integrated bioinformatics analysis shows integrin alpha 3 is a prognostic biomarker for pancreatic cancer. Last author DOI 10.1515/med-2022-0606↗
  8. The Crosstalk Between Immune Infiltration, Circulating Tumor Cells, and Metastasis in Pancreatic Cancer: Identification of HMGB3 From a Multiple Omics Analysis. Last author DOI 10.3389/fgene.2022.892177↗
  9. Circulating tumor cells in peripheral blood of pancreatic cancer patients and their prognostic role: a systematic review and meta-analysis. Last author DOI 10.1016/j.hpb.2019.11.003↗
  10. Knockdown of hsa_circ_0074298 suppressed the progression of pancreatic cancer by targeting the miR-519/SMOC2 axis Last author DOI 10.21203/rs.2.23308/v4↗
  11. Long non‑coding RNA CASC2 suppresses pancreatic cancer cell growth and progression by regulating the miR‑24/MUC6 axis. Last author DOI 10.3892/ijo.2019.4937↗
  12. The role of the fat mass and obesity-associated protein in the proliferation of pancreatic cancer cells. Last author DOI 10.3892/ol.2018.9873↗
  13. Diabetes mellitus stimulates pancreatic cancer growth and epithelial-mesenchymal transition-mediated metastasis via a p38 MAPK pathway. Last author DOI 10.18632/oncotarget.9533↗
  14. BRD4 promotes pancreatic ductal adenocarcinoma cell proliferation and enhances gemcitabine resistance. Last author DOI 10.3892/or.2015.3774↗
  15. The expression and phosphorylation of ezrin and merlin in human pancreatic cancer. Co-author DOI 10.3892/ijo.2014.2381↗
  16. Folate-chitosan-gemcitabine core-shell nanoparticles targeted to pancreatic cancer. Co-author DOI 10.3978/j.issn.1000-9604.2013.09.04↗
  17. Lentivirus-based DsRed-2-transfected pancreatic cancer cells for deep in vivo imaging of metastatic disease. First author DOI 10.1007/978-1-61779-797-2_5↗
  18. Marker expression in circulating cancer cells of pancreatic cancer patients. Co-author DOI 10.1016/j.jss.2010.05.007↗
  19. Resveratrol induces apoptosis in pancreatic cancer cells. Co-author PMID 21740780↗

Closest collaborators

The 25 strongest of 25 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Haodong Tang · 5 shared papers, 2022–2024 · strength 1.12
  2. Siyuan Tan · 3 shared papers, 2024 · strength 0.78
  3. Haifeng Li · 3 shared papers, 2024 · strength 0.78
  4. Fangfang Hu · 2 shared papers, 2022–2025 · strength 0.51
  5. Zeqian Yu · 6 shared papers, 2011–2023 · strength 0.45
  6. Hao Ye · 2 shared papers, 2022–2024 · strength 0.40
  7. Dafang Xu · 2 shared papers, 2020 · strength 0.35
  8. Zhibin Bai · 1 shared paper, 2025 · strength 0.33
  9. Peng Ping Xie · 1 shared paper, 2024 · strength 0.28
  10. Peng Xie · 1 shared paper, 2024 · strength 0.28
  11. Chiwen Bu · 1 shared paper, 2023 · strength 0.24
  12. Lishan Wang · 2 shared papers, 2016–2022 · strength 0.24
  13. Yang Yang · 1 shared paper, 2022 · strength 0.17
  14. Tao Cheng · 1 shared paper, 2022 · strength 0.17
  15. Hong Chen · 1 shared paper, 2020 · strength 0.16
  16. Yang Wang · 1 shared paper, 2020 · strength 0.16
  17. Zheng Zhang · 1 shared paper, 2022 · strength 0.16
  18. De-Tong Yang · 4 shared papers, 2011–2014 · strength 0.15
  19. Dawei Chen · 1 shared paper, 2019 · strength 0.12
  20. Xiaodong Tang · 1 shared paper, 2019 · strength 0.12
  21. Yong-Hui Wang · 2 shared papers, 2015–2016 · strength 0.12
  22. Robert M. Hoffman · 2 shared papers, 2011–2012 · strength 0.08
  23. Fangfang Hu · 1 shared paper, 2016 · strength 0.06
  24. Yang Yang · 1 shared paper, 2016 · strength 0.06
  25. Michael Bouvet · 1 shared paper, 2011 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.